Refractory Non-Small Cell Lung Cancer Clinical Trials in Washington D.C., District of Columbia

Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer